Clinical trial · no report yet · Phase 3
PANKU-Lung01
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
- NCT06382116 ↗
- Active, not recruiting
- Sichuan Baili Pharmaceutical Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 8 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- BL-B01D1; Pemetrexed+Cisplatin or Carboplatin
- Arms
- BL-B01D1 · Experimental
- Pemetrexed+Cisplatin or Carboplatin · Experimental
- Enrollment
- 432
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. with Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
- Start
- May 22, 2024
- Primary completion
- Aug 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06382116 · updated Jul 23, 2026